These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32740500)

  • 1. Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation.
    Gospodinova M; Sarafov S; Chamova T; Kirov A; Todorov T; Nakov R; Todorova A; Denchev S; Tournev I
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):688-695. PubMed ID: 32740500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
    Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
    Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
    Coutinho MC; Cortez-Dias N; Cantinho G; Conceição I; Oliveira A; Bordalo e Sá A; Gonçalves S; Almeida AG; de Carvalho M; Diogo AN
    Circ Cardiovasc Imaging; 2013 Sep; 6(5):627-36. PubMed ID: 23833285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.
    Tini G; Vianello PF; Gemelli C; Grandis M; Canepa M
    J Cardiovasc Transl Res; 2019 Dec; 12(6):514-516. PubMed ID: 30604309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.
    Damy T; Judge DP; Kristen AV; Berthet K; Li H; Aarts J
    J Cardiovasc Transl Res; 2015 Mar; 8(2):117-27. PubMed ID: 25743445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.
    Dungu JN; Papadopoulou SA; Wykes K; Mahmood I; Marshall J; Valencia O; Fontana M; Whelan CJ; Gillmore JD; Hawkins PN; Anderson LJ
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis.
    Gawor M; Holcman K; Franaszczyk M; Lipowska M; Michałek P; Teresińska A; Bilińska ZT; Rubiś P; Kostkiewicz M; Szot W; Podolec P; Grzybowski J
    Cardiol J; 2022; 29(6):985-993. PubMed ID: 32789836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.
    Sattianayagam PT; Hahn AF; Whelan CJ; Gibbs SD; Pinney JH; Stangou AJ; Rowczenio D; Pflugfelder PW; Fox Z; Lachmann HJ; Wechalekar AD; Hawkins PN; Gillmore JD
    Eur Heart J; 2012 May; 33(9):1120-7. PubMed ID: 21992998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transthyretin Cardiac Amyloidosis in Black Americans.
    Shah KB; Mankad AK; Castano A; Akinboboye OO; Duncan PB; Fergus IV; Maurer MS
    Circ Heart Fail; 2016 Jun; 9(6):e002558. PubMed ID: 27188913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
    Judge DP; Kristen AV; Grogan M; Maurer MS; Falk RH; Hanna M; Gillmore J; Garg P; Vaishnaw AK; Harrop J; Powell C; Karsten V; Zhang X; Sweetser MT; Vest J; Hawkins PN
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):357-370. PubMed ID: 32062791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
    Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
    Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).
    Bhuiyan T; Helmke S; Patel AR; Ruberg FL; Packman J; Cheung K; Grogan D; Maurer MS
    Circ Heart Fail; 2011 Mar; 4(2):121-8. PubMed ID: 21191093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
    Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
    JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare variant (p.Ser43Asn) of familial transthyretin amyloidosis associated with isolated cardiac phenotype: A case series with literature review.
    Papathanasiou M; Carpinteiro A; Kersting D; Jakstaite AM; Hagenacker T; Schlosser TW; Rischpler C; Rassaf T; Luedike P
    Mol Genet Genomic Med; 2021 Dec; 9(12):e1581. PubMed ID: 33345470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.